title: Effects of Enterococcus sp. isolated from deep seawater on inhibition of allergic responses in mice.
abstract: The objective of the present study was to assess the effects of Enterococcus sp. strain TN-3 isolated from deep seawater on inhibition of eosinophil accumulation, IgE production and active cutaneous anaphylaxis (ACA). We investigated the effects of viable and non-viable TN-3 on allergen-induced peritoneal eosinophil accumulation in mice. Viable (5.4 x 1010 colony-forming units per 60 mg) or non-viable TN-3 (60 mg) was orally administered to BALB/c mice that had been sensitised with the cedar pollen (Cryptomeria japonica) allergen. Oral administration of non-viable TN-3 was effective in suppressing eosinophil accumulation while viable TN-3 was ineffective. We also examined the dose-response relationship for non-viable TN-3 in regard to eosinophil accumulation, IgE production and ACA in allergen-primed mice. Non-viable TN-3 was orally administered at doses of 15 mg (low dose), 30 mg (medium dose) and 60 mg (high dose) to BALB/c mice that had been sensitised with cedar pollen allergen. The anti-allergic effects expressed as inhibition of eosinophil accumulation, IgE production and ACA were found at the low and high doses, but not at the medium dose. These results suggest that non-viable TN-3 exhibited anti-allergic effects at doses of 15 and 60 mg.
authors.affiliation: Central Research Laboratories, Nichinichi Pharmaceutical Corporation Ltd, 518-1417 Mie, Japan.
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kondoh
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hayashi
authors.forename: Mariko
authors.initials: M
authors.lastname: Okamori
authors.forename: Chie
authors.initials: C
authors.lastname: Motonaga
authors.forename: Tadao
authors.initials: T
authors.lastname: Enomoto
authors.forename: Lei
authors.initials: L
authors.lastname: Cheng
authors.forename: Takashi
authors.initials: T
authors.lastname: Shimada
mesh_terms: D000485:Allergens / Q000008:administration & dosage; D000707:Anaphylaxis / Q000276:immunology; D000818:Animals; D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D000942:Antigens, Bacterial / Q000008:administration & dosage*; D032485:Cryptomeria; D004305:Dose-Response Relationship, Drug; D016984:Enterococcus faecium / Q000276:immunology*; D004804:Eosinophils / Q000276:immunology; D005260:Female; D006969:Hypersensitivity, Immediate / Q000276:immunology / Q000517:prevention & control*; D007073:Immunoglobulin E / Q000097:blood; D007274:Injections, Intraperitoneal; D007958:Leukocyte Count; D051379:Mice; D008807:Mice, Inbred BALB C; D050296:Microbial Viability / Q000276:immunology; D023421:Models, Animal; D011058:Pollen; D012623:Seawater / Q000382:microbiology*; D014871:Water Microbiology
chemical_list: D000485:Allergens; D018926:Anti-Allergic Agents; D000942:Antigens, Bacterial; D007073:Immunoglobulin E